The webinar will include executives from PurpleLab and Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech's gCS Computational Catalysts. Genentech is owned by Roche.
Understanding the patient journey—from diagnosis through treatment—is crucial for drug developers aiming to create more effective therapies. Using non small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey — informing every phase of a drug's lifecycle, from clinical development to market access.
This webinar will include executives from PurpleLab and Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech's gCS Computational Catalysts. Genentech is owned by Roche.
No comments